{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"RVRC","limit":50},"count":11,"signals":[{"ticker":"RVRC","company":"Revium Rx.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":19,"context":"f antibiotics, making it valuable in treating resistant strains [2]. | | **** |  |  - |  Preclinical profile: Nano-Mupirocin formulations appeared to be well tolerated in preclinical studies, with no significant adverse effects reported [3]. However, these are pre-clinical indications that need to confirmed in appropriate clinical studies. | | **** |  |  - |  WHO Priority Pathogens: The World Health Organization (WHO) list","filed_date":"2026-03-31","accession":"0001213900-26-037573","full_text":"https://origin.rootz.global/static/filing/0001213900-26-037573.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RVRC","company":"Revium Rx.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"y. |  | |  |  |  |  | |  |  |  New tax laws or regulations that are enacted or existing tax laws and regulations that are interpreted, modified, or applied adversely to us or our customers may have a material adverse effect on our business and financial condition. |  | |  |  |  |  | |  |  |  We depend on our information technology and infrastructure so compromises could materially harm our ability to conduct business or","filed_date":"2025-02-14","accession":"0001213900-25-013823","full_text":"https://origin.rootz.global/static/filing/0001213900-25-013823.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RVRC","company":"Revium Rx.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":13,"context":"cer and Treasurer | | |  Daniel Bartal |  |  59 |  |  Chairman, Director | | |  Mordechai Jacobson |  |  55 |  |  Director | | |  Matti Munk |  |  53 |  |  Director | | ** ** **David Akunis,**59, was appointed Chief Executive Officer, effective December 23, 2024. He has 30 years experiences as senior corporate executive with an extensive knowledge in company development and venture capital investment. Between September 2010 and N","filed_date":"2025-02-14","accession":"0001213900-25-013823","full_text":"https://origin.rootz.global/static/filing/0001213900-25-013823.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RVRC","company":"Revium Rx.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":98,"match_count":11,"context":"Officer and Treasurer | | |  Bernard Bartal |  |  60 |  |  Chairman, Director | | |  Matti Munk |  |  53 |  |  Director | | |  Yoram Drucker |  |  59 |  |  Director | | **** **Amir Avraham, 49,** was appointed Chief Executive Officer on an interim basis, on May 22, 2025 following Mr. Akunis resignation from such position. Since February2024, Mr. Avraham has been a financial consultant with the Company, on a part time basis. Prior","filed_date":"2026-03-31","accession":"0001213900-26-037573","full_text":"https://origin.rootz.global/static/filing/0001213900-26-037573.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RVRC","company":"Revium Rx.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":83,"match_count":1,"context":"opment activities on commercially reasonable terms. ** *Foreign Exchange Risks* Our financial statements are denominated in U.S. dollars and financial results are denominated in U.S. dollars, while a significant portion of our business is conducted, and a substantial portion of our operating expenses are payable, in currencies other than the U.S. dollar. Exchange rate fluctuations may have an adverse impact on our future revenues,","filed_date":"2026-03-31","accession":"0001213900-26-037573","full_text":"https://origin.rootz.global/static/filing/0001213900-26-037573.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RVRC","company":"Revium Rx.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":16,"match_count":2,"context":"luctuations in response to the factors described in this section and other factors, many of which are beyond our control. Among the factors that could affect our stock price are: |  |  |  competitive pricing pressures; | | |  |  |  our ability to execute our development and commercialization strategy; | | |  |  |  our inability to obtain working capital financing, if needed; | | |  |  |  changing conditions in th","filed_date":"2026-03-31","accession":"0001213900-26-037573","full_text":"https://origin.rootz.global/static/filing/0001213900-26-037573.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RVRC","company":"Revium Rx.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":16,"match_count":2,"context":"ubject to penalties and may be precluded from marketing its product candidates if it fails to comply with extensive governmental regulations. | | |  |  |  | | |  |  |  Delays in the commencement, enrollment and completion of clinical trials could result in increased costs to us and delay or limit our ability to obtain regulatory approval for any of our product candidates. | | |  |  |  | | |  |  |  Ou","filed_date":"2025-02-14","accession":"0001213900-25-013823","full_text":"https://origin.rootz.global/static/filing/0001213900-25-013823.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RVRC","company":"Revium Rx.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":16,"match_count":2,"context":"luctuations in response to the factors described in this section and other factors, many of which are beyond our control. Among the factors that could affect our stock price are: |  |  |  competitive pricing pressures; | | |  |  |  our ability to market our services on a cost-effective and timely basis; | | |  |  |  our inability to obtain working capital financing, if needed; | | |  |  |  changing conditions in","filed_date":"2025-02-14","accession":"0001213900-25-013823","full_text":"https://origin.rootz.global/static/filing/0001213900-25-013823.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RVRC","company":"Revium Rx.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":13,"match_count":1,"context":"velopment activities on commercially reasonable terms. *Foreign Exchange Risks* Our financial statements are denominated in U.S. dollars and financial results are denominated in U.S. dollars, while a significant portion of our business is conducted, and a substantial portion of our operating expenses are payable, in currencies other than the U.S. dollar. Exchange rate fluctuations may have an adverse impact on our future revenues,","filed_date":"2025-02-14","accession":"0001213900-25-013823","full_text":"https://origin.rootz.global/static/filing/0001213900-25-013823.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RVRC","company":"Revium Rx.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":8,"match_count":1,"context":"re price of $0.001, of which 1,900,000 options were fully vested upon grant and the remaining 1,900,000 stock options are scheduled to vest on a quarterly basis over two years in equal quarterly installments of 237,500 options, beginning with the quarter ended March 31, 2024. The options are exercisable within eight years from grant date. The agreements contain customary confidentiality obligations w","filed_date":"2026-03-31","accession":"0001213900-26-037573","full_text":"https://origin.rootz.global/static/filing/0001213900-26-037573.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RVRC","company":"Revium Rx.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"platform_shift","strength":8,"match_count":1,"context":"|  |  Fee reductions for various regulatory activities. | | As part of our development strategy, we also intend to submit a Pediatric Investigation Plan (PIP), as required under EU regulation for all new marketing authorization applications, including orphan drugs. Given the increasing incidence of multidrug-resistant infections in pediatric populations, especially in neonatal and pediatric intensive care s","filed_date":"2026-03-31","accession":"0001213900-26-037573","full_text":"https://origin.rootz.global/static/filing/0001213900-26-037573.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"3ff257909d2dacb4c83fdfd333725f84efaf26d77d76212776f9acdb281f1d09","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"ddc0d322d476c5b5071d57c91b7b97d959f66736196f7e8c2eead24b60da7d5b","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":474,"hourly_limit":500,"remaining":26,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}